BidaskClub upgraded shares of Endo International (NASDAQ:ENDP) (TSE:ENL) from a hold rating to a buy rating in a research report released on Thursday.

A number of other analysts have also recently weighed in on ENDP. Zacks Investment Research cut Endo International from a buy rating to a hold rating in a research report on Tuesday, September 18th. Cantor Fitzgerald raised their price target on Endo International from $12.00 to $18.00 and gave the company a neutral rating in a report on Friday, October 19th. ValuEngine cut Endo International from a hold rating to a sell rating in a report on Thursday, November 8th. Cowen reissued a hold rating and issued a $9.00 price target on shares of Endo International in a report on Friday, November 9th. Finally, Canaccord Genuity raised Endo International from a hold rating to a buy rating and raised their price target for the company from $16.00 to $20.00 in a report on Friday, November 9th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Endo International has an average rating of Hold and a consensus price target of $15.73.

Endo International stock traded up $0.04 during mid-day trading on Thursday, reaching $9.50. 2,216,200 shares of the company were exchanged, compared to its average volume of 3,983,762. Endo International has a twelve month low of $5.27 and a twelve month high of $18.50. The stock has a market capitalization of $2.09 billion, a price-to-earnings ratio of 2.46, a PEG ratio of 3.41 and a beta of 0.92.

Endo International (NASDAQ:ENDP) (TSE:ENL) last posted its quarterly earnings data on Thursday, November 8th. The company reported $0.71 earnings per share for the quarter, topping analysts’ consensus estimates of $0.59 by $0.12. Endo International had a positive return on equity of 1,348.52% and a negative net margin of 37.82%. The company had revenue of $745.00 million during the quarter, compared to analysts’ expectations of $694.93 million. During the same period last year, the firm earned $0.91 EPS. The firm’s revenue for the quarter was down 5.3% on a year-over-year basis. As a group, equities analysts predict that Endo International will post 2.73 EPS for the current year.

In related news, Director William P. Montague sold 10,000 shares of Endo International stock in a transaction on Monday, December 10th. The stock was sold at an average price of $11.41, for a total transaction of $114,100.00. Following the completion of the transaction, the director now directly owns 64,888 shares of the company’s stock, valued at $740,372.08. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.80% of the company’s stock.

A number of hedge funds have recently modified their holdings of the stock. United Services Automobile Association raised its holdings in Endo International by 16.7% during the second quarter. United Services Automobile Association now owns 41,508 shares of the company’s stock worth $391,000 after purchasing an additional 5,933 shares during the last quarter. James Investment Research Inc. raised its holdings in Endo International by 594.9% during the third quarter. James Investment Research Inc. now owns 10,945 shares of the company’s stock worth $184,000 after purchasing an additional 9,370 shares during the last quarter. Neuberger Berman Group LLC acquired a new position in Endo International during the third quarter worth $202,000. Harvest Fund Management Co. Ltd acquired a new position in Endo International during the third quarter worth $223,000. Finally, Cim Investment Mangement Inc. acquired a new position in Endo International during the third quarter worth $262,000. 96.60% of the stock is owned by hedge funds and other institutional investors.

Endo International Company Profile

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Read More: What is the downside to momentum investing?

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.